Schwabe Stefan K.F. 4

4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Dec 15, 2020

Form 4

Period: 2020-12-14

Executive Vice President R&D

Transactions

Exercise/Conversion
Common Stock
2020-12-14$9.13/sh+50,000$456,500→ 52,772 total
Exercise/Conversion
Common Stock
2020-12-14$12.98/sh+3,653$47,416→ 56,425 total
Sale
Common Stock
2020-12-14$22.00/sh−3,653$80,369→ 2,772 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2020-12-14−3,653→ 46,347 total
Exercise: $12.98Exp: 2026-03-01→ Common Stock (3,653 underlying)
Sale
Common Stock
2020-12-14$21.86/sh−50,000$1,092,895→ 6,425 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2020-12-14−50,000→ 0 total
Exercise: $9.13Exp: 2025-03-03→ Common Stock (50,000 underlying)

Footnotes (5)

[F1]Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.5500 to $22.0300, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.0000 to $22.0100, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
[F4]The option vests in four equal annual installments beginning on March 3, 2016.
[F5]The option vests in four equal annual installments beginning on March 1, 2017.

Documents

2 files